uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: 17 analysts give uniQure an average rating of "Moderate Buy" (10 buys, 6 holds, 1 sell) with a mean 12‑month price target of $42.83.
• Recent results and valuation: Shares trade around $18.05 (1‑year range $8.73–$71.50) with a $1.13B market cap; the company remains unprofitable but beat the quarter with EPS of ($0.56) versus ($0.93) estimates and reported $5.57M in revenue.
• Ownership and insider activity: Insiders sold about 49,396 shares (~$722,734) last quarter, insiders own 4.79% while institutional investors hold roughly 78.83% of the stock.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seventeen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $42.8333.

QURE has been the subject of a number of analyst reports. Wolfe Research initiated coverage on uniQure in a report on Monday, February 23rd. They issued a "peer perform" rating for the company. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Stifel Nicolaus set a $14.00 price objective on uniQure in a research report on Monday, March 2nd. Cantor Fitzgerald reiterated a "neutral" rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Finally, The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $10.00 and gave the stock a "neutral" rating in a research report on Monday, April 20th.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 12,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares in the company, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares in the company, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 49,396 shares of company stock worth $722,734. Corporate insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Private Trust Co. NA purchased a new stake in shares of uniQure in the third quarter worth $28,000. Jones Financial Companies Lllp raised its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company's stock valued at $243,000 after purchasing an additional 533 shares in the last quarter. Arizona State Retirement System raised its position in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Price Performance

uniQure stock opened at $18.05 on Wednesday. uniQure has a one year low of $8.73 and a one year high of $71.50. The business has a fifty day moving average price of $16.97 and a 200-day moving average price of $26.12. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The firm has a market capitalization of $1.13 billion, a P/E ratio of -5.23 and a beta of 0.75.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. As a group, equities research analysts forecast that uniQure will post -3.6 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.